StreetInsider.com News Articles

Merck (MRK) PT Raised to $170 at Wells Fargo

Fri, 04 Sep 2026 06:49:34 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Merck (NYSE: MRK) to $170.00 (from $150.00) while maintaining a Overweight rating.

Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wed, 02 Sep 2026 06:45:00 -0400

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, Sept. 09, 2026, at 2:15 p.m. ET.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

About Merck

At Merck, known

Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wed, 02 Sep 2026 06:45:00 -0400

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

About Merck

At Merck, known

Form 3 Merck & Co., Inc. For: Sep 01 Filed by: Gupta Gaurav K

Tue, 01 Sep 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20260901/27012517.html

Merck (MRK) PT Raised to $180 at Wolfe Research

Tue, 25 Aug 2026 05:35:33 -0400

Wolfe Research analyst Alexandria Hammond raised the price target on Merck (NYSE: MRK) to $180.00 (from $155.00) while maintaining a Outperform rating.

The analyst comments "We now have MRK's earnings relatively flat 2028-2029. The positive outcome for partners Merck (MRK) and Moderna (MRNA) on INTerpath-001 (our initial take here) sent shares of both stocks up last Wednesday. The re-rating for MRK appears to point to some investor comfort ahead of Keytruda's IRA inclusion and patent expiry in 2029, which we'd agree with as we model earnings roughly flat in 2028 and 2029 ($8.89 and $8.79, respectively) and growing consistently afterward. Use

Merck (MRK) PT Raised to $180 at Wolfe Research

Tue, 25 Aug 2026 05:35:33 -0400

Wolfe Research analyst Alexandria Hammond raised the price target on Merck (NYSE: MRK) to $180.00 (from $155.00) while maintaining a Outperform rating.

Merck (MRK) PT Raised to $160 at Goldman Sachs

Fri, 21 Aug 2026 06:28:57 -0400

Goldman Sachs analyst Asad Haider raised the price target on Merck (NYSE: MRK) to $160.00 (from $140.00) while maintaining a Buy rating.

Merck (MRK) PT Raised to $170 at BMO Capital

Thu, 20 Aug 2026 07:37:33 -0400

BMO Capital analyst Evan David Seigerman raised the price target on Merck (NYSE: MRK) to $170.00 (from $142.00) while maintaining a Outperform rating.

Moderna stock pulls back after massive one-day rally: analysts weigh in

Thu, 20 Aug 2026 07:23:18 -0400

Investing.com -- Moderna shares pulled back sharply on Thursday, giving up a small chunk of Wednesday’s record-breaking rally after the stock rocketed as much as 177% on data showing its personalized cancer vaccine, developed with Merck, slowed the spread and recurrence of melanoma. Merck shares had jumped 12.6% on Wednesday alongside Moderna’s surge.

The positive results rippled through drug industry stocks more broadly, as investors weighed the potential for more blockbuster treatments to emerge from the field. It marked the second major oncology breakthrough in recent months, following a separate drug that succeeded in extending the lives of people with pancreatic

Moderna stock pulls back after massive one-day rally: analysts weigh in

Thu, 20 Aug 2026 07:23:18 -0400

Guggenheim Reiterates Buy Rating on Merck (MRK)

Thu, 20 Aug 2026 06:47:33 -0400

Guggenheim analyst Vamil Divan reiterated a Buy rating and $146.00 price target on Merck (NYSE: MRK).

The analyst commented: "MRK and partner MRNA announced this morning that their Phase 3 INTerpath-001 trial of INT combined with Keytruda met its primary endpoint of recurrence free survival (RFS) and key secondary endpoint of distant metastasis-free survival (DMFS) in patients with completely resected Stage IIB–IV melanoma, making it a historic first positive Phase 3 readout for a mRNA cancer therapy. The company stated they plan to submit these data to regulatory agencies and emphasized the primary endpoint of RFS has been the registrational endpoint

Guggenheim Reiterates Buy Rating on Merck (MRK)

Thu, 20 Aug 2026 06:47:33 -0400

Guggenheim analyst Vamil Divan reiterated a Buy rating and $146.00 price target on Merck (NYSE: MRK).

RBC Capital Downgrades Merck (MRK) to Sector Perform

Thu, 20 Aug 2026 05:04:56 -0400

RBC Capital analyst Trung Huynh downgraded Merck (NYSE: MRK) from Outperform to Sector Perform with a price target of $150.00 (from $142.00).

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $152.20 yesterday.

Merck (MRK) call put ratio 3 calls to 1 put with a focus on 6K contracts of November 135 puts

Thu, 20 Aug 2026 04:50:53 -0400

Merck (NYSE: MRK) 30-day call option implied volatility is 34; compared to its 52-week range of 22 to 36. Call put ratio 3 calls to 1 put with a focus on 6K contracts of November 135 puts amid wide price movement.

UBS Downgrades Merck (MRK) to Neutral

Thu, 20 Aug 2026 02:49:29 -0400

UBS analyst Matthew Weston downgraded Merck (NYSE: MRK) from Buy to Neutral with a price target of $150.00.

The analyst comments: “Following a period of strong share price performance and renewed investor confidence in Merck's three divisional model, we see the current valuation as broadly up to speed with events. We maintain our €150 price target and downgrade to Neutral (from Buy). We raise 2026E Core EPS by 3% but lower 2027E+ sales by an average 2%. UBS sales forecasts are now 2-4% below VA sales consensus 2027-31E.

We continue to forecast 9-10% underlying demand for bioprocess consumables, underpinned by biopharma pipelines

UBS Downgrades Merck (MRK) to Neutral

Thu, 20 Aug 2026 02:49:29 -0400

UBS analyst Matthew Weston downgraded Merck (NYSE: MRK) from Buy to Neutral with a price target of $150.00.

We continue to forecast 9-10% underlying demand for bioprocess consumables, underpinned by biopharma pipelines

Moderna (MRNA) PT Raised to $89 at Morgan Stanley

Wed, 19 Aug 2026 16:23:38 -0400

Morgan Stanley analyst Terence Flynn raised the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $39.00) while maintaining a Equalweight rating.

The analyst comments "We are Equal-weight Moderna. While we believe there is long-term upside for Moderna, we believe the significant valuation increase associated with the success of the COVID-19 vaccine limits the near-term upside. ▪ We believe Moderna's mRNA drug development platform is more diversified and scalable compared with competitors, and is validated through broad partnership with Merck. ▪ We see vaccines and INT as the key valuation drivers of the company."

Moderna (MRNA) PT Raised to $89 at Morgan Stanley

Wed, 19 Aug 2026 16:23:38 -0400

Morgan Stanley analyst Terence Flynn raised the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $39.00) while maintaining a Equalweight rating.

Moderna (MRNA) PT Raised to $89 at Morgan Stanley

Wed, 19 Aug 2026 16:23:38 -0400

Morgan Stanley analyst Terence Flynn raised the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $39.00) while maintaining a Equalweight rating.

Moderna (MRNA) PT Raised to $89 at Morgan Stanley

Wed, 19 Aug 2026 16:23:38 -0400

Morgan Stanley analyst Terence Flynn raised the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $39.00) while maintaining a Equalweight rating.

Morgan Stanley Upgrades Merck (MRK) to Overweight

Wed, 19 Aug 2026 16:22:56 -0400

(Updated - August 19, 2026 4:22 PM EDT)